ABG
Ally Bridge Group Portfolio holdings
AUM
$114M
This Quarter Return
+2.67%
1 Year Return
+41.64%
3 Year Return
+246.39%
5 Year Return
–
10 Year Return
–
AUM
$356M
AUM Growth
+$356M
(-14%)
Cap. Flow
-$43.3M
Cap. Flow
% of AUM
-12.14%
Top 10 Holdings %
Top 10 Hldgs %
56.65%
Holding
39
New
7
Increased
5
Reduced
6
Closed
11
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$15.3M |
| 2 |
Nautilus Biotechnolgy
NAUT
|
$15.2M |
| 3 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
$13.4M |
| 4 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$12M |
| 5 |
Arvinas
ARVN
|
$10.5M |
Top Sells
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$27M |
| 2 |
Intellia Therapeutics
NTLA
|
$21.4M |
| 3 |
Atea Pharmaceuticals
AVIR
|
$11.4M |
| 4 |
iTeos Therapeutics
ITOS
|
$11M |
| 5 |
Oric Pharmaceuticals
ORIC
|
$10.1M |
Sector Composition
| 1 | Healthcare | 97.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDVL
1
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $35.8M | 8.89% | 2,920,780 | – | – |
|
2
Natera
NTRA
$23.1B
| $24.8M | 6.15% | 218,000 | – | – |
|
3
Fate Therapeutics
FATE
$120M
| $23.4M | 5.82% | 270,000 | – | – |
|
|
SYRS
4
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $18.7M | 4.66% | 3,439,895 +300,000 | +10% | +$1.63M |
|
|
5
Arvinas
ARVN
$568M
| $18.5M | 4.59% | 240,000 +135,747 | +130% | +$10.5M |
|
|
CERE
6
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $17.3M | 4.3% | 675,670 -1,052,920 | -61% | -$27M |
|
7
Repligen
RGEN
$6.88B
| $16.5M | 4.09% | 82,500 | – | – |
|
8
Nuvation Bio
NUVB
$1.02B
| $15.9M | 3.95% | 1,708,091 -291,909 | -15% | -$2.72M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $15.7M | 3.91% | 859,910 +179,142 | +26% | +$3.28M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $15.3M | 3.81% | +95,000 | New | +$15.3M |
|
|
11
Nautilus Biotechnolgy
NAUT
$85.9M
| $15.2M | 3.76% | +1,500,000 | New | +$15.2M |
|
|
12
Intellia Therapeutics
NTLA
$1.22B
| $15.1M | 3.75% | 93,127 -131,873 | -59% | -$21.4M |
|
|
CYT
13
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $13.4M | 3.33% | +626,843 | New | +$13.4M |
|
14
Cogent Biosciences
COGT
$1.69B
| $13.2M | 3.27% | 1,622,591 | – | – |
|
|
NSTG
15
DELISTED
NanoString Technologies, Inc.
NSTG
| $12M | 2.98% | +185,000 | New | +$12M |
|
16
IDEAYA Biosciences
IDYA
$2.15B
| $10.7M | 2.66% | 510,407 +480,407 | +1,601% | +$10.1M |
|
17
Iovance Biotherapeutics
IOVA
$807M
| $10.6M | 2.63% | 406,986 | – | – |
|
18
ESSA Pharma
EPIX
$11.4M
| $10.4M | 2.58% | 363,185 | – | – |
|
|
NVTA
19
DELISTED
Invitae Corporation
NVTA
| $10.1M | 2.51% | +300,000 | New | +$10.1M |
|
20
Gossamer Bio
GOSS
$562M
| $9.54M | 2.37% | +1,175,000 | New | +$9.54M |
|
|
21
Atea Pharmaceuticals
AVIR
$267M
| $8.02M | 1.99% | 373,288 -530,400 | -59% | -$11.4M |
|
22
Bolt Biotherapeutics
BOLT
$9.85M
| $6.37M | 1.58% | 412,267 +124,542 | +43% | +$1.93M |
|
23
Apellis Pharmaceuticals
APLS
$3.48B
| $5.37M | 1.33% | 85,000 -145,000 | -63% | -$9.16M |
|
24
Adicet Bio
ACET
$59.9M
| $4.37M | 1.09% | 425,000 | – | – |
|
25
ARS Pharmaceuticals
SPRY
$1.15B
| $3.97M | 0.99% | 128,572 | – | – |
|